Printer Friendly

MARION MERRELL DOW COMMENTS ON COURT CASE

 MARION MERRELL DOW COMMENTS ON COURT CASE
 KANSAS CITY, Mo., Oct. 13 /PRNewswire/ -- Marion Merrell Dow Inc.


(NYSE: MKC) today issued the following statement:
 The U.S. Supreme Court today agreed to hear an appeal of a Ninth Circuit U.S. Court of Appeals ruling in the Daubert lawsuit involving Bendectin(R). In December 1991, the appeals court had upheld an earlier ruling by the U.S. District Court in San Diego granting summary judgment against the plaintiffs because there was insufficient admissible evidence to go to trial. In that decision, the appeals court followed the precedent of three other federal circuits and held that the plaintiffs could not use evidence based on a scientific methodology that diverged from what is generally recognized as acceptable in the field. Plaintiffs have asked the Supreme Court to hear arguments on what the company believes are narrow evidentiary issues. The court's decision to hear arguments is not a ruling on the merits of the case.
 Marion Merrell Dow strongly believes that this lawsuit is without merit. Courts that have decided similar cases have overwhelmingly found that there is no evidence that Bendectin caused birth defects, yet some members of the plaintiffs' bar continue to pursue spurious product liability actions. As a matter of principle, the company will continue to vigorously contest this lawsuit and similar lawsuits. The company does not believe that it would have a material exposure financially, even if the case were decided unfavorably.
 -0- 10/13/92
 /CONTACT: David M. Thompson or Richard M. Johnson of Marion Merrell Dow, 816-966-4000/
 (MKC) CO: Marion Merrell Dow Inc. ST: Missouri IN: MTC SU:


BB -- DV008 -- 9388 10/13/92 13:55 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 13, 1992
Words:280
Previous Article:NEVER-BEFORE-SEEN PHOTOS OF EDDIE MURPHY STOLEN; MOTOWN OFFERS $10,000 REWARD FOR ALBUM COVER NEGATIVES
Next Article:LADBROKE AT THE MEADOWS ISSUES STATEMENT
Topics:


Related Articles
MARION MERRELL DOW ANNOUNCES SETTLEMENT WITH GENERIC MAKER ON LOOK-ALIKE TABLETS
ALZA, CYANAMID, ELAN AND MARION MERRELL CONCLUDE AGREEMENTS AND REACH AN OUT-OF-COURT SETTLEMENT
MARION MERRELL DOW AND RHONE-POULENC RORER REACH AGREEMENT TO SETTLE DISPUTES REGARDING ANTIHYPERTENSIVE DRUGS
MARION MERRELL DOW & TANABE SEIYAKU
MARION MERRELL DOW FILES SUIT OVER COMPETITOR'S CLAIMS THAT DRUGS ARE SIMILAR
MARION MERRELL DOW AND TANABE SEIYAKU FILE INTERNATIONAL TRADE COMPLAINT AGAINST CARDIZEM IMITATORS
MARION MERRELL DOW COMMENTS ON COURT CASE
MARION MERRELL DOW INC. FILES LAWSUIT OVER PATENT INFRINGEMENT
DILTIAZEM PATENT PROCESS CONFIRMED -- CLEARS WAY FOR MARION MERRELL DOW CASE AT INTERNATIONAL TRADE COMMISSION
COURT RULES IN FAVOR OF ALZA & MARION MERRELL DOW, DECLARES CIBA-GEIGY NICOTINE PATENT INVALID

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters